Liquidia Corp

Noticias y eventos de Liquidia Corp (LQDA)

$68.630

-1.036 (-1.51%)Al cierre

Noticias de LQDA

Eventos de LQDA

9/3 08:00

Liquidia's Yutrepia Receives FDA Fast Track Designation

Liquidia announced that the FDA has granted Fast Track designation to Yutrepia inhalation powder for the treatment of Raynaud's phenomenon associated with systemic sclerosis. The potential use of Yutrepia in SSc-RP is currently under clinical development, and its safety and efficacy for this indication have not been evaluated by any regulatory authority.

8/12 07:00

Liquidia Reports Q2 Revenue of $171.68M, Exceeds Expectations

Reports Q2 revenue $171.68M, consensus $168.48M. Roger Jeffs, Liquidia's CEO, said: "We are pleased by the sustained adoption of YUTREPIA as the inhaled prostacyclin of choice. The inhaled category has grown almost 40% since launch, and YUTREPIA has captured an ever-increasing share of that growth. We are building on that momentum by strengthening the clinical evidence for YUTREPIA in PAH and PH-ILD patients transitioning from other therapies, and advancing studies in new indications that may broaden its impact. Having reset the bar for tolerability and dose flexibility with YUTREPIA, we are excited to have begun site activation and enrollment in Re-Spire, our pivotal study for L606, which we believe can raise that bar even further, beyond any therapy currently available or in development."

6/4 12:10

Liquidia Shares Rise 17.6% to $65.50

Liquidia is up 17.6%, or $9.81 to $65.50.

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empieza gratis